Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 18,000 shares of the firm’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $109.93, for a total value of $1,978,740.00. Following the sale, the director now directly owns 193,142 shares of the company’s stock, valued at $21,232,100.06. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Stryker Corp. (NYSE:SYK) traded up 0.29% during trading on Monday, reaching $111.76. The company’s stock had a trading volume of 179,078 shares. The stock has a market cap of $41.85 billion, a price-to-earnings ratio of 25.43 and a beta of 0.86. The company has a 50 day moving average of $114.21 and a 200-day moving average of $114.92. Stryker Corp. has a 12-month low of $86.68 and a 12-month high of $123.55.

Stryker Corp. (NYSE:SYK) last released its quarterly earnings data on Thursday, October 27th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.02. The firm earned $2.83 billion during the quarter, compared to analyst estimates of $2.81 billion. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The business’s quarterly revenue was up 17.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.25 earnings per share. Analysts forecast that Stryker Corp. will post $5.78 EPS for the current year.

Insider Buying and Selling by Quarter for Stryker Corp. (NYSE:SYK)

Several institutional investors have recently added to or reduced their stakes in SYK. Blue Chip Partners Inc. raised its position in shares of Stryker Corp. by 0.3% in the second quarter. Blue Chip Partners Inc. now owns 1,757 shares of the medical technology company’s stock worth $211,000 after buying an additional 6 shares during the last quarter. Washington Trust Bank raised its position in shares of Stryker Corp. by 0.5% in the second quarter. Washington Trust Bank now owns 3,040 shares of the medical technology company’s stock worth $364,000 after buying an additional 15 shares during the last quarter. Wetherby Asset Management Inc. raised its position in shares of Stryker Corp. by 0.3% in the second quarter. Wetherby Asset Management Inc. now owns 6,242 shares of the medical technology company’s stock worth $748,000 after buying an additional 18 shares during the last quarter. Douglas Lane & Associates LLC raised its position in shares of Stryker Corp. by 0.7% in the second quarter. Douglas Lane & Associates LLC now owns 2,945 shares of the medical technology company’s stock worth $353,000 after buying an additional 20 shares during the last quarter. Finally, Wade G W & Inc. raised its position in shares of Stryker Corp. by 1.0% in the third quarter. Wade G W & Inc. now owns 2,230 shares of the medical technology company’s stock worth $260,000 after buying an additional 22 shares during the last quarter. 73.55% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on the company. Zacks Investment Research upgraded Stryker Corp. from a “hold” rating to a “buy” rating and set a $119.00 price target for the company in a research note on Tuesday, November 15th. Needham & Company LLC reiterated a “hold” rating on shares of Stryker Corp. in a research note on Sunday, November 13th. BMO Capital Markets upgraded Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 price target for the company in a research note on Tuesday, November 1st. They noted that the move was a valuation call. Canaccord Genuity set a $127.00 price target on Stryker Corp. and gave the stock a “buy” rating in a research note on Sunday, October 30th. Finally, Oppenheimer Holdings Inc. set a $122.00 price target on Stryker Corp. and gave the stock a “hold” rating in a research note on Sunday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the stock. Stryker Corp. has an average rating of “Buy” and a consensus price target of $122.38.

About Stryker Corp.

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.